# Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

> **NCT03464864** · PHASE1 · COMPLETED · sponsor: **Mannkind Corporation** · enrollment: 36 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Treprostinil Inhalation Powder

## Key facts

- **NCT ID:** NCT03464864
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-09
- **Primary completion:** 2018-06-05
- **Final completion:** 2018-06-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2018-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03464864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03464864, "Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03464864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*